刘光美
[摘要] 目的 探讨硼替佐米联合地塞米松治疗多发性骨髓瘤的临床疗效。方法 便利选取2016年2月—2017年2月期间该院80例多发性骨髓瘤患者,根据随机数字法,将其分为对照组(常规化疗)和观察组(硼替佐米联合地塞米松化疗),每组各40例,比较两组临床疗效,化疗前后骨痛程度、血钙、血磷水平变化情况,以及化疗期间不良反应。 结果 与对照组相比,观察组总有效率明显增高(92.5% vs 55.0%,P<0.05);与对照组相比,观察组患者化疗后骨痛程度,血钙、血磷水平均显著降低,差异有统计学意义(P<0.05);两组都没有出现严重不良反应。 结论 硼替佐米联合地塞米松能够明显提高多发性骨髓瘤的临床疗效,为治疗提供新的治疗方向。
[关键词] 硼替佐米;地塞米松;多发性骨髓瘤
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2017)11(b)-0133-03
[Abstract] Objective This paper tries to study the clinical efficacy of bortezomib combined with dexamethasone in the treatment of multiple myeloma. Methods Convenient selected 80 patients with multiple myeloma in this hospital from February 2016 to February 2017 were randomized into the control group (with routine chemotherapy) and the observation group (with bortezomib and dexamethasone) according to the random number method. The clinical efficacy, bone pain, blood calcium and phosphorus level changes on pre- and post-chemotherapy, and the adverse reactions of the two groups were compared. Results Compared with the control group, the total effective rate was significantly increased in the observation group (92.5% vs 55.0%, P<0.05); compared with the control group, the bone pain, blood calcium and phosphorus level on post-chemotherapy were obviously reduced in the observation group, with statistical difference (P<0.05); no serious adverse reactions occurred in two groups. Conclusion The treatment of bortezomib combined with dexamethasone can significantly improve the clinical efficacy of multiple myeloma and provide a new treatment direction.
[Key words] Bortezomib; Dexamethasone; Multiple myeloma
多发性骨髓瘤作为临床常见的血液科疾病,属于浆细胞克隆性血液系统恶性肿瘤范畴,有报道称[1],其发病率约占血液肿瘤的10%,好发于中老年患者,患者多表现为骨痛、贫血等临床症状,严重影响着患者的健康,并呈现低龄化发病趋势。联合化疗是目前治疗多发性骨髓瘤的有效方法,而硼替佐米作为新型肿瘤靶向药物,对于多发性骨髓瘤的治疗发挥了明显的推进作用,明显改善了多发性骨髓瘤患者的预后效果,其临床疗效得到了普遍认可[2]。有报道称[3],硼替佐米联合地塞米松治疗多发性骨髓瘤患者,具有较高的临床疗效及较好的治疗安全性。该研究2016年2月—2017年2月期间该院40例多发性骨髓瘤患者,给予硼替佐米联合地塞米松化疗,取得了较好的临床效果,现报道如下。
1 资料与方法
1.1 一般资料
便利选取该院80例多发性骨髓瘤患者,根据随机数字法,将其分为对照组(常规化疗)和观察组(硼替佐米联合地塞米松化療),每组各40例。……